Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration

Masami Tanaka, Keiko Tanaka, Shoji Tsuji, Akihiro Kawata, Sigeyuki Kojima, Tomomi Kurokawa, Jun ichi Kira, Masafumi Takiguchi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To determine a peptide that reacts with cytotoxic T cells (CTL) of patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies with either HLA A24 or B27 supertype. Method: We studied CTL activity of four patients, three were HLA A24-positive and one did not have HLA A24 but had B27 supertype. After an incubation of mononuclear cells with or without peptide and IL-2, CD8-rich fraction was prepared by treatment with Magnetic Cell Sorting system (MACS) twice. CTL activity was calculated by 51Cr release from transfectant, C1RA* 2402 as target cells. The peptide-binding assay was examined by flow cytometry. Results: Two of three HLA A 24-positive patients demonstrated CTL activity against the Yo peptide, AYRARALEL. CTL activity was found to be 19.5% and 11.7% at the effector/target (E/T) ratio of 23:1 and 11:1, respectively. A patient who did not have HLA A24 but had A2 and B27 supertype possessed a CTL activity of 19.4% with 15:1 as E/T ratio. The peptide could bind to HLA A* 2402 molecules but not to A* 0201. Conclusions: We showed CTL activity in two of three Japanese patients with HLA A24 by using HLA A* 2402 transfectant cells as the target. In addition, we identified the first Japanese patient who had B27 supertype, and suggested that the same peptide, AYRARALEL, could be recognized by CTL in this patient.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalJournal of the Neurological Sciences
Volume188
Issue number1-2
DOIs
Publication statusPublished - Jul 15 2001

Fingerprint

Paraneoplastic Cerebellar Degeneration
HLA-A24 Antigen
HLA-B27 Antigen
T-Lymphocytes
Peptides
HLA-A Antigens
Proteins
varespladib methyl
Interleukin-2
Anti-Idiotypic Antibodies
Flow Cytometry

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. / Tanaka, Masami; Tanaka, Keiko; Tsuji, Shoji; Kawata, Akihiro; Kojima, Sigeyuki; Kurokawa, Tomomi; Kira, Jun ichi; Takiguchi, Masafumi.

In: Journal of the Neurological Sciences, Vol. 188, No. 1-2, 15.07.2001, p. 61-65.

Research output: Contribution to journalArticle

Tanaka, Masami ; Tanaka, Keiko ; Tsuji, Shoji ; Kawata, Akihiro ; Kojima, Sigeyuki ; Kurokawa, Tomomi ; Kira, Jun ichi ; Takiguchi, Masafumi. / Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. In: Journal of the Neurological Sciences. 2001 ; Vol. 188, No. 1-2. pp. 61-65.
@article{d061589b92c44b32818c8903fb1ebaef,
title = "Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration",
abstract = "Objective: To determine a peptide that reacts with cytotoxic T cells (CTL) of patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies with either HLA A24 or B27 supertype. Method: We studied CTL activity of four patients, three were HLA A24-positive and one did not have HLA A24 but had B27 supertype. After an incubation of mononuclear cells with or without peptide and IL-2, CD8-rich fraction was prepared by treatment with Magnetic Cell Sorting system (MACS) twice. CTL activity was calculated by 51Cr release from transfectant, C1RA* 2402 as target cells. The peptide-binding assay was examined by flow cytometry. Results: Two of three HLA A 24-positive patients demonstrated CTL activity against the Yo peptide, AYRARALEL. CTL activity was found to be 19.5{\%} and 11.7{\%} at the effector/target (E/T) ratio of 23:1 and 11:1, respectively. A patient who did not have HLA A24 but had A2 and B27 supertype possessed a CTL activity of 19.4{\%} with 15:1 as E/T ratio. The peptide could bind to HLA A* 2402 molecules but not to A* 0201. Conclusions: We showed CTL activity in two of three Japanese patients with HLA A24 by using HLA A* 2402 transfectant cells as the target. In addition, we identified the first Japanese patient who had B27 supertype, and suggested that the same peptide, AYRARALEL, could be recognized by CTL in this patient.",
author = "Masami Tanaka and Keiko Tanaka and Shoji Tsuji and Akihiro Kawata and Sigeyuki Kojima and Tomomi Kurokawa and Kira, {Jun ichi} and Masafumi Takiguchi",
year = "2001",
month = "7",
day = "15",
doi = "10.1016/S0022-510X(01)00548-2",
language = "English",
volume = "188",
pages = "61--65",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration

AU - Tanaka, Masami

AU - Tanaka, Keiko

AU - Tsuji, Shoji

AU - Kawata, Akihiro

AU - Kojima, Sigeyuki

AU - Kurokawa, Tomomi

AU - Kira, Jun ichi

AU - Takiguchi, Masafumi

PY - 2001/7/15

Y1 - 2001/7/15

N2 - Objective: To determine a peptide that reacts with cytotoxic T cells (CTL) of patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies with either HLA A24 or B27 supertype. Method: We studied CTL activity of four patients, three were HLA A24-positive and one did not have HLA A24 but had B27 supertype. After an incubation of mononuclear cells with or without peptide and IL-2, CD8-rich fraction was prepared by treatment with Magnetic Cell Sorting system (MACS) twice. CTL activity was calculated by 51Cr release from transfectant, C1RA* 2402 as target cells. The peptide-binding assay was examined by flow cytometry. Results: Two of three HLA A 24-positive patients demonstrated CTL activity against the Yo peptide, AYRARALEL. CTL activity was found to be 19.5% and 11.7% at the effector/target (E/T) ratio of 23:1 and 11:1, respectively. A patient who did not have HLA A24 but had A2 and B27 supertype possessed a CTL activity of 19.4% with 15:1 as E/T ratio. The peptide could bind to HLA A* 2402 molecules but not to A* 0201. Conclusions: We showed CTL activity in two of three Japanese patients with HLA A24 by using HLA A* 2402 transfectant cells as the target. In addition, we identified the first Japanese patient who had B27 supertype, and suggested that the same peptide, AYRARALEL, could be recognized by CTL in this patient.

AB - Objective: To determine a peptide that reacts with cytotoxic T cells (CTL) of patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies with either HLA A24 or B27 supertype. Method: We studied CTL activity of four patients, three were HLA A24-positive and one did not have HLA A24 but had B27 supertype. After an incubation of mononuclear cells with or without peptide and IL-2, CD8-rich fraction was prepared by treatment with Magnetic Cell Sorting system (MACS) twice. CTL activity was calculated by 51Cr release from transfectant, C1RA* 2402 as target cells. The peptide-binding assay was examined by flow cytometry. Results: Two of three HLA A 24-positive patients demonstrated CTL activity against the Yo peptide, AYRARALEL. CTL activity was found to be 19.5% and 11.7% at the effector/target (E/T) ratio of 23:1 and 11:1, respectively. A patient who did not have HLA A24 but had A2 and B27 supertype possessed a CTL activity of 19.4% with 15:1 as E/T ratio. The peptide could bind to HLA A* 2402 molecules but not to A* 0201. Conclusions: We showed CTL activity in two of three Japanese patients with HLA A24 by using HLA A* 2402 transfectant cells as the target. In addition, we identified the first Japanese patient who had B27 supertype, and suggested that the same peptide, AYRARALEL, could be recognized by CTL in this patient.

UR - http://www.scopus.com/inward/record.url?scp=0035878566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035878566&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(01)00548-2

DO - 10.1016/S0022-510X(01)00548-2

M3 - Article

C2 - 11489286

AN - SCOPUS:0035878566

VL - 188

SP - 61

EP - 65

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -